Skip to main content
. Author manuscript; available in PMC: 2012 Mar 22.
Published in final edited form as: Am J Psychiatry. 2011 May 15;168(8):831–839. doi: 10.1176/appi.ajp.2011.08121844

Figure 2.

Figure 2

Average MMSE, ADAS-Cog, and Cognitive Summary scores by study period and by antipsychotic treatment vs. placebo. Decreases in MMSE and the Cognitive Summary, and increases in ADAS-Cog are indicative of cognitive decline. Mean raw scores at baseline, week 12, week 24, and week 36, respectively, were: MMSE placebo: 15.2, 13.7, 15.2, 13.4; MMSE antipsychotic: 15.2, 14.8, 14.2, 13.0; Cognitive Summary placebo: .05, −.06, 0, −.04; Cognitive Summary antipsychotic: .05, .03, −.01, −.13; ADAS-Cog placebo: 34.4, 36.1, 33.4, 35.4; ADAS-Cog antipsychotic: 34.4, 34.1, 35.4, 37.8.